Page 129 - ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Namma Mysuru connection for desi Covaxin

Namma Mysuru connection for desi Covaxin December 19, 2020 Bharat Biotech Joint Managing Director says it may cost around Rs.300 per dose; Committed to distribute vaccine to ‘Bharat’ first Mysore/Mysuru: All know that Hyderabad-based Bharat Biotech is involved in developing Covaxin, a possible vaccine for the dreaded COVID-19 pandemic. But hardly a few know that two persons behind this company had stayed in ‘Namma Mysuru’ for a few years before flying to United States of America (USA) to pursue higher studies on a scholarship. The couple, Dr. Krishna Ella, Chairman and Managing Director (CMD) and Suchitra K. Ella, Joint Managing Director of Bharat Biotech, was staying near Sterling Theatre in Vidyaranyapuram and then shifted to a house near Ramakrishna Vidyashala in Yadavagiri for 5-6 years.

United statesAndhra pradeshKrishna ellaSuchitrak ellaSuchitra ellaNational institute of virologyNational excellenceUniversity of agricultural sciencesIndian council of medical researchResearch institutesWorld health organisationBharat biotech joint managing directorHyderabad based bharat biotechNamma mysuruManaging directorJoint managing director

Coronavirus: 22,890 fresh COVID-19 cases in India, 4 6% lower than yesterday; 99 79 lakh total cases, 1,44,789 deaths

Up to 338 more deaths were reported from across the country in the past 24 hours. New Delhi: New Coronavirus Cases Updates: India recorded 22,890 new coronavirus cases in the past 24 hours, taking the total caseload to over 99.79 lakh. The number of fresh infections is 4.6 per cent down since Thursday. Up to 338 more deaths were reported in this time, taking total fatality to 1,44,789 till now. Over 31,087 recovered since yesterday, taking the overall figure to 95,20,827. India remains the second worst-hit country in the world after the US. Here are the top-10 developments on this front from the past 24 hours: Maharashtra remained the worst-hit state with over 18.86 lakh cases and nearly 48,500 deaths till now. Other states in the top-five badly hit category are Karnataka, Andhra Pradesh, Tamil Nadu, and Kerala.

United statesTamil naduHarsh vardhanBiontech covidCenters for diseaseUniversity of washington health sciencesUnion healthNew cases fallAndhra pradeshLancet respiratory medicineUnion health minister harsh vardhanHyderabad based bharat biotechDisease controlWashington health sciencesSouth americanPresident emmanuel macron

Coronavirus Vaccine | Covaxin triggered immune response, no serious adverse effect, shows Phase I trial

Coronavirus Vaccine | Covaxin triggered immune response, no serious adverse effect, shows Phase I trial Covaxin, India s indigenous COVID-19 vaccine, has trigerred immune response with no serious adverse effects, according to Phase I trail results. Updated: Wed, 16 Dec 2020 08:52 PM IST New Delhi | Jagran News Desk: Covaxin, India s indigenous COVID-19 vaccine developed by Hyderabad-based Bharat Biotech, has triggered immune response with no serious adverse effects, according to Phase I trial results released by the company. The company said that the vaccine induced (a) neutralising antibody (an immune response) and was well-tolerated in all dose groups with no vaccine-related serious adverse events . After the first vaccination, local and systemic adverse events were predominantly mild or moderate in severity and resolved rapidly, without any prescribed medication. The most common adverse event was pain at the injection site, which resolved spontaneously, it added.

Indian council of medical researchJagran news deskHyderabad based bharat biotechBharat biotechIndian councilMedical researchஇந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சிஜாக்ரான் செய்தி மேசைஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக்பாரத் பயோடெக்இந்தியன் சபைமருத்துவ ஆராய்ச்சி

Covid vaccine: Bharat Biotech s Covaxin shows robust results in phase-1 trials

Covid vaccine: Bharat Biotech s Covaxin shows robust results in phase-1 trials
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Bharat biotechImmunogenicity trialBiological evansHyderabad based bharat biotechIndian councilபாரத் பயோடெக்உயிரியல் எவன்ஸ்ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக்இந்தியன் சபை

Coronavirus outbreak: Bharat Biotech vaccine generates robust immune responses

A homegrown candidate vaccine developed by the Hyderabad-based Bharat Biotech has generated “robust” immune responses, including high levels of neutralising antibodies, against the novel coronavirus, government and industry researchers said on Wednesday. In their first scientific paper on human clinical trials of their candidate vaccine, the researchers have also described observing possible hints of immune memory responses critical for long-term efficacy triggered by all three formulations they tested. These early results do not permit assessment of the vaccine’s efficacy in protecting people from the coronavirus infection but had guided India’s drug regulatory agency’s decision to approve the efficacy trials that started last month and seek to enrol around 26,000 volunteers.

United kingdomSerum instituteIndian council of medical researchSerum institute of indiaCentral drugs standard control organisationHyderabad based bharat biotechBharat biotechMedical researchஒன்றுபட்டது கிஂக்டம்சீரம் நிறுவனம்இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சிசீரம் நிறுவனம் ஆஃப் இந்தியாமைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக்பாரத் பயோடெக்மருத்துவ ஆராய்ச்சி